Home/Filings/4/A/0001855763-22-000020
4/A//SEC Filing

Downey Gregory 4/A

Accession 0001855763-22-000020

CIK 0001348362other

Filed

Oct 17, 8:00 PM ET

Accepted

Oct 18, 6:31 PM ET

Size

14.0 KB

Accession

0001855763-22-000020

Insider Transaction Report

Form 4/AAmended
Period: 2022-10-14
Downey Gregory
Chief Financial Officer
Transactions
  • Purchase

    common shares

    2022-10-14$2.09/sh+121$2531,954 total
Holdings
  • Stock Options

    Exercise: $5.04From: 2022-04-15Exp: 2026-04-15Common Shares (4,000 underlying)
    8,000
  • Stock Options

    Exercise: $7.08From: 2021-06-08Exp: 2026-06-08Common Shares (8,000 underlying)
    25,000
  • Stock Options

    Exercise: $2.91From: 2022-08-29Exp: 2027-08-29Common Shares (11,000 underlying)
    46,000
  • Stock Options

    Exercise: $5.04From: 2021-04-15Exp: 2026-04-15Common Shares (4,000 underlying)
    4,000
  • common shares

    1,833
  • Stock Options

    Exercise: $5.04From: 2023-04-15Exp: 2026-04-15Common Shares (4,000 underlying)
    12,000
  • Stock Options

    Exercise: $5.31From: 2022-04-26Exp: 2026-04-26Common Shares (5,000 underlying)
    17,000
  • Stock Options

    Exercise: $6.23From: 2021-09-01Exp: 2026-09-01Common Shares (10,000 underlying)
    35,000
Footnotes (1)
  • [F1]This Form 4A is being filed to correct the transaction code for the open market purchase made by Mr. Downey as originally notated as a grant or award in the Form 4 filed on October 18, 2022.

Issuer

Lexaria Bioscience Corp.

CIK 0001348362

Entity typeother

Related Parties

1
  • filerCIK 0001855801

Filing Metadata

Form type
4/A
Filed
Oct 17, 8:00 PM ET
Accepted
Oct 18, 6:31 PM ET
Size
14.0 KB